Fluorodeoxyglucose | CAS#29702-43-0 | Anticancer glucose derivative

MedKoo Cat#: 463779 | Name: Fluorodeoxyglucose

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

2-deoxy-2-fluoro-D-Glucose (Fluorodeoxyglucose) is a derivative of glucose with anticancer activity. It inhibits the growth of 143B osteosarcoma cells grown under normoxic and hypoxic conditions when used at concentrations of 6 and 24 mM.

Chemical Structure

Fluorodeoxyglucose

CAS#29702-43-0

Theoretical Analysis

MedKoo Cat#: 463779

Name: Fluorodeoxyglucose

CAS#: 29702-43-0

Chemical Formula: C6H11FO5

Exact Mass: 182.0591

Molecular Weight: 182.15

Elemental Analysis: C, 39.56; H, 6.09; F, 10.43; O, 43.92

Price and Availability

Size	Price	Availability
100mg	USD 450.00	2 Weeks
250mg	USD 850.00	2 Weeks
500mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

FDG; 2-deoxy-2-fluoro-D-Glucose; 2-FG; 2FG; 2 FG; Fluorodeoxyglucose; 2-fluoro-2-deoxy-D-Glucose;

IUPAC/Chemical Name

(2R,3S,4R,5R)-2-fluoro-3,4,5,6-tetrahydroxyhexanal

InChi Key

AOYNUTHNTBLRMT-SLPGGIOYSA-N

InChi Code

InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1

SMILES Code

OC[C@H]([C@H]([C@@H]([C@H](C=O)F)O)O)O

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 182.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chen D, Chang C, Chen M, Zhang Y, Zhao X, Zhang T, Wang Z, Yan J, Zhu H, Zheng L, Zhao K. Unusual disseminated Talaromyces marneffei infection mimicking lymphoma in a non-immunosuppressed patient in East China: a case report and review of the literature. BMC Infect Dis. 2020 Oct 28;20(1):800. doi: 10.1186/s12879-020-05526-1. PMID: 33115429; PMCID: PMC7594432. 2: Mayerhöfer ME, Haug A. Hybridbildgebung bei Lymphom [Hybrid imaging in lymphoma]. Radiologe. 2020 May;60(5):376-385. German. doi: 10.1007/s00117-020-00676-4. PMID: 32296856. 3: Kim MS, Kim EK, Choi JY, Oh JK, Chang SA. Clinical Utility of [18F]FDG-PET /CT in Pericardial Disease. Curr Cardiol Rep. 2019 Aug 2;21(9):107. doi: 10.1007/s11886-019-1193-x. PMID: 31376028. 4: Kim JK, Jeong CW, Ku JH, Kim HH, Kwak C. Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. J Cancer. 2019 May 21;10(10):2237-2242. doi: 10.7150/jca.29714. PMID: 31258727; PMCID: PMC6584413. 5: Ogawa M, Namikawa T, Oki T, Iwabu J, Munekage M, Maeda H, Tamura T, Yatabe T, Kitagawa H, Dabanaka K, Sugimoto T, Kobayashi M, Hanazaki K. Gastric outlet obstruction caused by metastatic tumor of the stomach originating from primary breast cancer: A case report. Mol Clin Oncol. 2018 Nov;9(5):523-526. doi: 10.3892/mco.2018.1722. Epub 2018 Sep 17. PMID: 30402234; PMCID: PMC6200976. 6: Flechsig P, Hural O, Kreuter M, Eichhorn M, HEUßEL G, Sachpekidis C, Kauczor HU, Haberkorn U, Heussel CP, Eichinger M. Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD. In Vivo. 2018 Nov- Dec;32(6):1457-1462. doi: 10.21873/invivo.11399. PMID: 30348701; PMCID: PMC6365762. 7: Ohta Y, Kawahara Y, Tadokoro K, Sato K, Sasaki R, Takahashi Y, Takemoto M, Hishikawa N, Yamashita T, Asano T, Inomata T, Abe K. Asymmetrical and Isolated Hypoglossal Nerve Palsy Accompanied by a New Subset of Anti-ganglioside Antibodies in a Patient with Diffuse Large B Cell Lymphoma. Intern Med. 2019 Jan 15;58(2):283-286. doi: 10.2169/internalmedicine.1269-18. Epub 2018 Aug 24. PMID: 30146587; PMCID: PMC6378144. 8: Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å. Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy. Adv Radiat Oncol. 2018 Feb 13;3(2):130-138. doi: 10.1016/j.adro.2017.12.007. PMID: 29904737; PMCID: PMC6000081. 9: Yanai A, Itoh M, Hirakawa H, Yanai K, Tashiro M, Harada R, Yoshikawa A, Yamamoto S, Ohuchi N, Ishida T. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer. Tohoku J Exp Med. 2018 May;245(1):13-19. doi: 10.1620/tjem.245.13. PMID: 29731479. 10: Jung JH, Son SH, Kim DH, Lee J, Jeong SY, Lee SW, Park HY, Lee J, Ahn BC. CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer. Medicine (Baltimore). 2017 Nov;96(46):e8438. doi: 10.1097/MD.0000000000008438. PMID: 29145250; PMCID: PMC5704795. 11: Niccoli S, Boreham DR, Phenix CP, Lees SJ. Non-radioactive 2-deoxy-2-fluoro- D-glucose inhibits glucose uptake in xenograft tumours and sensitizes HeLa cells to doxorubicin in vitro. PLoS One. 2017 Nov 2;12(11):e0187584. doi: 10.1371/journal.pone.0187584. PMID: 29095925; PMCID: PMC5667878. 12: Wang Y, Li M, Diao R, Tung B, Zhang D, Li Y. Experimental study on the therapeutic effect and underlining mechanisms of positron in pancreatic cancer cells. Oncotarget. 2017 Jun 5;8(31):51652-51662. doi: 10.18632/oncotarget.18366. PMID: 28881676; PMCID: PMC5584277. 13: Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017 Jul 23;7(11):2956-2964. doi: 10.7150/thno.20491. PMID: 28824728; PMCID: PMC5562228. 14: Chandra P, Dhake S, Purandare N, Agrawal A, Shah S, Rangarajan V. Role of FDG PET/CT in Diagnostic Evaluation of Granulocytic Sarcomas: A Series of 12 Patients. Indian J Nucl Med. 2017 Jul-Sep;32(3):198-202. doi: 10.4103/ijnm.IJNM_10_17. PMID: 28680203; PMCID: PMC5482015. 15: Oka S, Kanagawa M, Doi Y, Schuster DM, Goodman MM, Yoshimura H. PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. Theranostics. 2017 May 15;7(7):2048-2064. doi: 10.7150/thno.19883. PMID: 28656060; PMCID: PMC5485422. 16: Ertay T, Sencan Eren M, Karaman M, Oktay G, Durak H. 18F-FDG- PET/CT in Initiation and Progression of Inflammation and Infection. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):47-52. doi: 10.4274/mirt.18291. PMID: 28613196; PMCID: PMC5472086. 17: Shin HB, Sheen H, Lee HY, Kang J, Yoon DK, Suh TS. Digital Imaging and Communications in Medicine (DICOM) information conversion procedure for SUV calculation of PET scanners with different DICOM header information. Phys Med. 2017 Dec;44:243-248. doi: 10.1016/j.ejmp.2017.05.063. Epub 2017 May 24. PMID: 28551298. 18: Ishino S, Sugita T, Kondo Y, Okai M, Tsuchimori K, Watanabe M, Mori I, Hosoya M, Horiguchi T, Kamiguchi H. Glucose uptake of the muscle and adipose tissues in diabetes and obesity disease models: evaluation of insulin and β3-adrenergic receptor agonist effects by 18F-FDG. Ann Nucl Med. 2017 Jun;31(5):413-423. doi: 10.1007/s12149-017-1169-0. Epub 2017 Apr 11. PMID: 28401400. 19: Kircher M, Lapa C. Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation. Curr Cardiovasc Imaging Rep. 2017;10(2):6. doi: 10.1007/s12410-017-9400-x. Epub 2017 Feb 10. PMID: 28357026; PMCID: PMC5352761. 20: Matsusaka Y, Nakahara T, Takahashi K, Iwabuchi Y, Nishime C, Kajimura M, Jinzaki M. 18F-FDG-labeled red blood cell PET for blood-pool imaging: preclinical evaluation in rats. EJNMMI Res. 2017 Dec;7(1):19. doi: 10.1186/s13550-017-0266-3. Epub 2017 Feb 27. PMID: 28244021; PMCID: PMC5328895.